10-Q: CVRx Q3 2025: Barostim Drives Revenue Growth Amid Losses

CVRx, Inc. reported a 10% revenue increase in Q3 2025, driven by U.S. Barostim sales and improved gross margins, despite continued net losses.

Summary

• Revenue for the three months ended September 30, 2025, increased by 10% to $14.7 million, up from $13.4 million in the prior year period.
• Revenue for the nine months ended September 30, 2025, increased by 13% to $40.6 million, compared to $36.0 million in the prior year period.
• U.S. revenue grew 10% to $13.5 million in Q3 2025 and 13% to $36.9 million for the nine months ended September 30, 2025.
• European revenue increased 12% to $1.2 million in Q3 2025 and 17% to $3.7 million for the nine months ended September 30, 2025.
• Gross margin improved to 87% in Q3 2025 (from 83% in Q3 2024) and 85% for the nine months ended September 30, 2025 (from 84% in 9M 2024), primarily due to increased average selling price and manufacturing efficiencies.
• Net loss for Q3 2025 was $12.9 million, a slight improvement from $13.1 million in Q3 2024.
• Net loss for the nine months ended September 30, 2025, was $41.4 million, an improvement from $49.3 million in the prior year period.
• Cash and cash equivalents decreased to $85.1 million as of September 30, 2025, from $105.9 million at December 31, 2024.
• Net cash used in operating activities for the nine months ended September 30, 2025, was $30.4 million, compared to $31.1 million in the prior year period.
• New Category I CPT codes for Barostim implant and follow-up services will take effect January 1, 2026, expected to improve prior authorization predictability and physician payment.
• The At-the-Market (ATM) offering, which raised $9.5 million in gross proceeds during the nine months ended September 30, 2025, was terminated on November 6, 2025, with plans for a new registration statement and sales agreement for future ATM activity.
• Barostim received final approval and certificates of compliance under the EU Medical Devices Regulation (MDR) on April 9, 2025, ensuring continued market access in the European Economic Area.

Sentiment

Score: 7

Explanation: While the company continues to report net losses and negative cash flow, the significant revenue growth, improved gross margins, and positive regulatory developments (new CPT codes, EU MDR compliance) indicate strong operational progress and future potential. The decrease in net loss year-over-year is also a positive sign. The need for future capital raises is acknowledged but managed.

Positives

• Strong revenue growth of 10% in Q3 2025 and 13% for the nine months ended September 30, 2025, driven by increased U.S. and European sales of Barostim.
• Significant improvement in gross margin to 87% in Q3 2025 (from 83% in Q3 2024) and 85% for the nine months ended September 30, 2025 (from 84% in 9M 2024), attributed to higher average selling prices and manufacturing efficiencies.
• Net loss decreased for both the three-month ($12.9 million vs. $13.1 million) and nine-month ($41.4 million vs. $49.3 million) periods compared to the prior year, indicating progress in managing operational costs relative to revenue growth.
• Expansion of U.S. active implanting centers to 250 as of September 30, 2025 (from 208 in Q3 2024) and sales territories to 50 (from 45 in Q3 2024), demonstrating successful commercialization efforts.
• The Centers for Medicare & Medicaid Services (CMS) released the final 2026 Medicare Physician Fee Schedule, including new Category I CPT codes for Barostim, which is expected to eliminate automatic denials and improve prior authorization predictability starting January 1, 2026.
• Barostim achieved final approval and certificates of compliance under the EU Medical Devices Regulation (MDR) on April 9, 2025, securing its market position in the European Economic Area.

Negatives

• Continued significant operating losses and negative cash flows from operations, with management expecting this trend to persist in the foreseeable future.
• Cash and cash equivalents decreased by $20.8 million during the nine months ended September 30, 2025, to $85.1 million, indicating ongoing cash burn.
• Interest expense increased by 54% in Q3 2025 and 53% for the nine months ended September 30, 2025, due to higher levels of borrowings under the Loan Agreement.
• The company remains highly dependent on a single product, Barostim, making it vulnerable to market acceptance fluctuations or competitive pressures.
• Reliance on a limited number of third-party suppliers for components makes the company vulnerable to supply shortages, performance degradation, price fluctuations, and ongoing supply chain disruptions.
• The At-the-Market (ATM) offering was terminated, requiring the filing of a new registration statement and sales agreement to enable future equity raises, which could introduce uncertainty or delays in funding.
• European sales territories decreased from six as of September 30, 2024, to five as of September 30, 2025, despite revenue growth in the region.

Risks

• A history of significant losses, which are expected to continue, with no assurance of achieving or sustaining profitability.
• High dependence on a single product, Barostim; failure to increase market acceptance in the U.S. would negatively impact business, liquidity, and results of operations.
• Limited commercial sales experience marketing and selling Barostim, and inability to maintain and grow sales and marketing capabilities would hinder sustained and increasing product revenue.
• The necessity to continually demonstrate the merits of Barostim to physicians and patients for adoption.
• Inadequate coverage and reimbursement from third-party payers would negatively impact revenue.
• Operating in a highly competitive industry with larger, well-established companies that have substantially greater resources.
• Failure to receive access to hospitals may decrease sales.
• Dependence upon third-party manufacturers and, in some cases, a limited number of suppliers, making the company vulnerable to supply shortages, loss or degradation in performance of suppliers, price fluctuations, and ongoing supply chain disruptions.
• Manufacturing risks that could adversely affect the ability to manufacture products and reduce gross margin and profitability.
• Potential for product liability claims that could be costly, divert management's attention, and harm reputation.
• Future involvement in lawsuits to protect or enforce intellectual property or defend against intellectual property disputes, which could be expensive, time-consuming, and unsuccessful.
• Failure to retain key executives or recruit and hire new employees could adversely affect operations and financial results.
• The need to continue obtaining long-term clinical data regarding the safety and effectiveness of products, which could impact future adoption and regulatory approvals.
• Extensive governmental regulation in foreign jurisdictions, such as Europe, and failure to comply with applicable requirements could cause the business to suffer.
• Cash balances are maintained with financial institutions in excess of insured limits, posing credit risk.
• Inflationary factors, such as increases in cost of goods sold and operating expenses, may adversely affect operating results if selling prices do not increase commensurately.
• Utilization of Net Operating Losses (NOLs) may be subject to an annual limitation due to ownership change limitations provided by Section 382 of the Internal Revenue Code and similar state provisions.

Future Outlook

The company expects to continue incurring net losses for the next several years due to planned investments in commercialization efforts. Future revenue growth is anticipated through expanding the dedicated salesforce, increasing awareness of Barostim among payers, physicians, and patients, and seeking expanded labeling for the product. Gross margin is expected to be positively affected over time by selling more product through the direct sales force and by increasing production volumes. Research and development expenses are expected to increase in absolute dollars as the company continues to develop enhancements to Barostim. Selling, general and administrative expenses are expected to increase in absolute dollars but decrease as a percentage of revenue as revenue grows. Management believes that existing cash resources, together with cash from operations, will be sufficient to meet forecasted requirements for operating liquidity, capital expenditures, and debt services for at least the next two years, until principal payments on the Innovatus Loan Agreement begin in November 2027.

Management Comments

• Management expects that operating losses and negative cash flows from operations could continue in the foreseeable future. There is no assurance that the Company will generate sufficient product sales to produce positive earnings or cash flows.
• We expect the transition to Category I will eliminate the automatic denials regularly seen with Category III codes and improve prior authorization predictability to fairly pay physicians for the procedure.
• As a result of the planned investments to fund our commercialization efforts, we expect to continue to incur net losses for the next several years, which may require additional funding and could include future equity and debt financing.

Industry Context

CVRx operates in the competitive medical device industry, specializing in neuromodulation solutions for cardiovascular diseases, particularly heart failure with reduced Ejection Fraction (HFrEF) and resistant hypertension. Barostim is positioned as the first and only commercially available neuromodulation device for HFrEF. The company's strategy emphasizes expanding its direct sales force, educating physicians and patients, and securing favorable reimbursement, especially from Medicare, which covers an estimated 67% of the target patient population. Regulatory compliance, including FDA approval in the U.S. and CE Mark/EU MDR certification in Europe, is crucial for market access. The industry is characterized by the presence of large, well-established competitors and a continuous need for clinical evidence and R&D to drive product adoption and innovation.

Management Changes

Corporate Governance

Legal Proceedings

• Not currently a party to any material legal proceedings.

Related Party Transactions

• Johnson & Johnson Innovation JJDC, Inc. exercised common stock warrants for 604,000 shares of common stock through a net exercise transaction during the nine months ended September 30, 2024.

Stakeholder Impact

• Shareholders: Potential for dilution from future equity raises; positive impact from revenue growth and improved gross margins; risk of continued losses and cash burn.
• Employees: Benefit from stock-based compensation plans (stock options, RSUs, ESPP) and 401(k) matching contributions; potential for growth opportunities with company expansion.
• Customers (Hospitals/Physicians): Improved reimbursement predictability with new CPT codes for Barostim; continued education and support from CVRx sales force.
• Patients: Continued access to Barostim therapy for heart failure and resistant hypertension; potential for expanded indications and product enhancements.
• Suppliers: Continued business due to manufacturing needs, but reliance on limited suppliers poses risk.
• Creditors: Debt obligations under the Innovatus Loan Agreement are being met, with principal payments starting in November 2027.

Next Steps

• File a new registration statement on Form S-3 to replace the existing one expiring November 15, 2025.
• Enter into a new sales agreement to permit continued At-the-Market (ATM) offering activity in the future.
• Continue to expand the U.S. commercial infrastructure and sales force.
• Promote awareness among physicians, hospitals, and patients to accelerate adoption of Barostim.
• Continue to develop and disseminate clinical evidence supporting the benefits of Barostim.
• Raise awareness among payers to build upon reimbursement for Barostim.
• Invest in research and development to foster innovation and develop product enhancements.
• Leverage manufacturing capacity to further improve gross margins.
• Evaluate the potential impact of the One Big Beautiful Bill Act (OBBBA) on consolidated financial statements and related disclosures.
• Undergo annual audits by the Notified Body to verify continued compliance with EU Medical Devices Regulation (MDR) requirements.

Key Dates

Recommendation

CVRx demonstrates strong revenue growth and improving gross margins, indicating increasing market acceptance for Barostim. The positive regulatory developments, such as the new Category I CPT codes and EU MDR compliance, are significant catalysts for future growth and market access. However, the company continues to incur substantial net losses and negative cash flows, and relies heavily on a single product. While the financial position is stable for the near term, the need for future capital raises and the competitive landscape warrant a 'hold' recommendation. Investors should monitor the company's progress towards profitability and successful execution of its commercialization strategy.

Keywords

CVRx, Barostim, Heart Failure, HFrEF, Neuromodulation, Medical Device, SEC 10-Q, Financial Results, Q3 2025, Revenue Growth, Gross Margin, Net Loss, Reimbursement, FDA, CE Mark, EU MDR, Capital Raise, Stock Options, ESPP